The earnings call presented a mixed outlook with significant progress in the OpRegen and OPC1 programs, including promising clinical results and strategic partnerships. However, financial challenges, including a substantial impairment expense and warrant liabilities, contributed to a notable net loss.

Company Guidance -

Q3 2025

During the Lineage Cell Therapeutics Second Quarter 2025 Conference Call, several key metrics and updates were provided, highlighting the company's strategic and operational progress. Notably, the OpRegen program for dry AMD with geographic atrophy demonstrated a mean gain of vision of 9 letters in treated eyes over three years, compared to an 11-letter loss in untreated eyes, showing a 20-letter difference in mean visual acuity. This suggests potential for a one-time functional cure. Additionally, Lineage's financials for the second quarter of 2025 reported total revenues of $2.8 million, a significant rise from $1.4 million in the same period in 2024. Operating expenses were $22.5 million, including a noncash impairment expense on the VAC platform, leading to a net loss of $30.5 million or $0.13 per share. The company has $42.3 million in cash reserves, projected to support operations into Q1 2027, with potential for $37 million from Roche and Genentech following trial advancements. Lineage is also pursuing nondilutive funding strategies, including milestone payments and grants, to sustain and expand its pipeline, such as the OPC1 spinal cord injury program and other emerging therapeutic areas.

OpRegen Program Positive Developments

The OpRegen program, an off-the-shelf RPE transplant for dry AMD, showed consistent and durable treatment effects with a 20-letter difference in visual acuity over 3 years between treated and untreated eyes. There are now four independent groups reporting vision gains from RPE transplants, including Lineage's partners Roche and Genentech.

New Strategic Direction and Partnerships

Lineage plans to capitalize on its directed differentiation expertise and recent manufacturing achievements to expand into new therapeutic areas. Partnership with Roche and Genentech provides clinical and development expertise, financial backing, and commercial infrastructure for a global ophthalmology product launch.

OPC1 Program Progress

The first participant in the DOSED study for OPC1, a spinal cord injury treatment, was successfully administered, marking an important milestone. New delivery systems and improved manufacturing processes are being tested, potentially enhancing safety and efficacy.

Financial Position and Revenue Growth

Lineage's cash position was $42.3 million as of June 30, 2025, expected to support operations into Q1 of 2027. Total revenues were $2.8 million, a net increase of $1.4 million compared to the same period in 2024.

Lineage Therap (LCTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LCTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.03 / -	-0.02	―	―	―
Aug 12, 2025	2025 (Q2)	-0.03 / -0.13	-0.03	-333.33% (-0.10)	―
May 13, 2025	2025 (Q1)	-0.03 / -0.02	-0.04	50.00% (+0.02)	―
Mar 10, 2025	2024 (Q4)	-0.03 / -0.02	-0.03	33.33% (<+0.01)	―
Nov 14, 2024	2024 (Q3)	-0.04 / -0.02	-0.04	50.00% (+0.02)	―
Aug 08, 2024	2024 (Q2)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.04 / -0.04	-0.03	-33.33% (-0.01)	―
Mar 07, 2024	2023 (Q4)	-0.04 / -0.03	-0.03	0.00% (0.00)	―
Nov 09, 2023	2023 (Q3)	-0.04 / -0.04	-0.04	0.00% (0.00)	―
Aug 10, 2023	2023 (Q2)	-0.04 / -0.03	-0.04	25.00% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LCTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$1.01	$1.03	+1.98%
May 13, 2025	$0.47	$0.46	-2.13%
Mar 10, 2025	$0.53	$0.53	0.00%
Nov 14, 2024	$0.88	$0.86	-2.27%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Lineage Cell Therapeutics, Inc. (LCTX) report earnings?

Lineage Cell Therapeutics, Inc. (LCTX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Lineage Cell Therapeutics, Inc. (LCTX) earnings time?

Lineage Cell Therapeutics, Inc. (LCTX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LCTX EPS forecast?

LCTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing